Stock Ratings / Health Care / PCSA / dividends

SCNX (28) ADXN (48) LGVN (27) GELS (54) ⌘ Pro Terminal →

Processa Pharmaceuticals Inc. (PCSA) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.89 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.89

Processa Pharmaceuticals Inc. (PCSA) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $5.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PCSA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PCSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.89 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PCSA ranks #494 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PCSA compare to SCNX and ADXN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PCSA?

▼

Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $0 in revenue, -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.89 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCSA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY PCSA SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 55.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.77+1.1% Next Q

Q2 (-2Q)

Grade E$1.79+1.7% Next Q

Q3 (-1Q)

Grade E$1.82+3.8% Next Q

Current

Grade D-$1.89-7.6% Hist 90D α

Trajectory: E (31) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PCSA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PCSA currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.84) and Max Pain ($1.98) forces dealer call-delta covering toward $10.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCSA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PCSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PCSA)

✓Walkthrough of PCSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PCSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.48%⚡ TESTING RESISTANCE

2026-11-03O $1.89H $1.89L $1.89C $1.89VOL 25.4K

RES: $2.06SUP: $0.79SMA50: $1.84SMA200: $2.34

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCSA Butterfly Map → + Track PCSA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PCSA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PCSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCSA)

Health Care Rank #494 of 1016 ⚔️ SCNX vs PCSA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCSA vs. SCNX, ADXN, LGVN, GELS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Processa Pharmaceuticals Inc. (PCSA) ranks #494 by composite RQD confidence (39/100, grade D-) and #936 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, PCSA leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with PCSA at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PCSA ACTIVE Processa Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.3M	Benchmark Subject
SCNX Scienture Holdings Inc.	E	28/100	—	76.8%	-35.0%	-7.74%	$5.3M	/scnx-vs-pcsa →
ADXN Addex Therapeutics Ltd	D	48/100	—	—	—	+5.46%	$5.3M	/adxn-vs-pcsa →
LGVN Longeveron Inc. (Class A)	E	27/100	—	67.0%	-35.0%	-4.57%	$5.3M	/lgvn-vs-pcsa →
GELS Gelteq Limited	D+	54/100	—	—	—	-3.14%	$5.2M	/gels-vs-pcsa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533743

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Processa Pharmaceuticals Inc. (PCSA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.6M, operating cash flow of -$11.4M, and free cash flow of -$11.4M (-1.2% YoY). On the balance sheet, PCSA closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$13.6M	-$11.4M	-$11.4M	$7.8M	—
FY2024 (FY)	2024-12-31	$0	-$11.8M	-$11.2M	-$11.2M	$3.2M	—
FY2023 (FY)	2023-12-31	$0	-$11.1M	-$8.1M	-$8.1M	—	—

3. PCSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PCSA compare to SCNX and ADXN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PCSA?

Where is PCSA trading relative to its 50-day, 200-day, and 52-week technical levels?

PCSA last traded at $1.89 (0.00% on volume of 25,373 shares), positioning the stock +2.72% above its 50-day simple moving average ($1.84) and -19.23% below its 200-day simple moving average ($2.34). Across its 52-week range of $1.04 to $10.25, PCSA sits at the 9.2% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).

PCSA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does PCSA pay a dividend and is it safe?

Processa Pharmaceuticals Inc. (PCSA) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: PCSA RQD Cockpit PCSA 12M Forecast PCSA Earnings & Move PCSA Dividends & DRIP PCSA Insiders & 13F PCSA Whale Options PCSA Profit Sankey PCSA News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PCSA — Processa Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:53:10Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PCSA scores 39 out of 100 and receives a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental cash engine: 7 / 20. The pillar notes ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to offset its reported losses.
Whale 13F flow: 8 / 20. The pillar summarizes institutional accumulation and options positioning. The underlying holder detail is not provided in this dataset, so the score reflects the rating's assessment without itemized support here.
Insider conviction: 5 / 20. The lowest pillar, covering SEC Form 4 and Congressional PTR cluster flow. A low score signals weak insider-level conviction signals in the rating's inputs.
Macro regime fit: 9 / 20. The pillar cites beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive cushion.
Forensic balance sheet: 10 / 20. The pillar references Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5. These metrics sit in the middle-to-weak range and point to a balance sheet that warrants close monitoring.

Taken together, the rating frames PCSA as a high-risk, cash-consuming equity where the upside case depends on events outside the current financial profile. Valuation tradeoffs are significant: with a market capitalization of $5.3M and no reported positive earnings, traditional earnings-based valuation is not available in source data. Upside drivers would need to come from pipeline progress and corporate actions rather than current operations.

Business

Processa Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. Per the company profile, the market capitalization is listed as $0.0B. Specific product lines, customer base, and revenue model are not available in source data. Per the SEC financials, reported revenue was $0.0M in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the periods provided. Per recent news, the company has announced a pipeline item (a BTK inhibitor, VT-7208) and a merger with Vidya Therapeutics; details beyond these headlines are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-14.0M	$-13.6M	N/A	$-11.4M	$5.5M	N/A
FY 2024	$0.0M	$-12.1M	$-11.8M	N/A	$-11.2M	$1.2M	N/A
FY 2023	$0.0M	$-11.5M	$-11.1M	N/A	$-8.1M	N/A	N/A

Per the SEC financials, the company reported operating losses and net losses in each period shown, with gross, operating, and net margins all listed at 0% in market data. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are cited within the forensic balance sheet pillar; the Piotroski score is weak. Debt/Equity is listed as 0.5. Reported cash rose from $1.2M (FY 2024) to $5.5M (FY 2025), while FCF remained negative in every period.

Recent Catalysts & News Wire Analysis

Green catalyst (per Kalkine): Clearance of an FDA IND for the BTK inhibitor VT-7208 in urticaria, alongside a Generian partnership, flagged as a pipeline expansion.
Yellow market-wire items: Several reports (Yahoo Finance Canada, TradingView, Stock Titan, Kalkine Media, GlobeNewswire) cover a proposed reverse stock split following the Vidya Therapeutics merger and corporate/pipeline progress updates. A reverse split is a structural corporate action; its implications for share count and price are not detailed in source data.
Risk watch: The reverse split proposal and the weak balance sheet metrics are the primary items to monitor. Per the market data, the stock trades at $1.89 against a 52-week high of $10.25.
Proprietary signals: None provided in the Butterfly Supply-Chain Graph.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. An investor should note that the pipeline (VT-7208) and the Vidya merger are the company's main external linkages per the news wire, but their supply-chain relationships are not mapped in the provided graph.

Open Questions

What is the company's revenue model and does it expect any product revenue, given $0.0M reported in each period?
What are the terms, share count impact, and timing of the proposed reverse stock split and the Vidya Therapeutics merger?
What is the current cash runway relative to the FY 2025 FCF of $-11.4M, and how will the company fund operations?
What are the terms and milestones of the Generian partnership and the VT-7208 development program?
Who are the institutional and insider holders behind the RQD pillar scores, given that the holders dataset is empty?

PCSA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Processa Pharmaceuticals Inc. (PCSA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PCSA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 17h ago

Processa Pharmaceuticals, Inc. (PCSA) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

Processa Pharmaceuticals, Inc. Estimates – NASDAQ:PCSA

TradingView report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

Processa Pharmaceuticals, Inc. SEC Filing (Oct 26, 2026)

Stock Titan report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Kalkine • 1d ago

Processa Pharmaceuticals (NASDAQ:PCSA) Clears FDA IND for BTK Inhibitor VT-7208 in Urticaria, Expands Pipeline With Generian Partnership

Kalkine report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Processa Pharmaceuticals Proposes Reverse Stock Split Following Merger with Vidya Therapeutics

Kalkine Media report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics

GlobeNewswire report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's Intraday Session - Mobile-health Network (NASDAQ:MNDR), XORTX Th

Benzinga report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An estimated 1.6M to 2M U.S. adults have chronic hives. FDA clears a planned drug study.

Stock Titan report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PCSA Bull vs. Bear Conversation Board — What's Your Call at $1.89?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PCSA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.66 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PCSA (D- • RQD 39/100) a Buy at $1.89?

Welcome to the PCSA (Processa Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.47 (-22.2%)

Spot @ $1.89

Pump the brakes on PCSA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PCSA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Processa Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.36 (+24.9%)

Spot @ $1.89

PCSA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PCSA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.89 (52-wk range $1.04 - $10.25), any beat on forward guidance forces shorts and underweight funds to chase.